Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

TABLE 3

Dapagliflozin treatment of ZDF rats over 15 days results in reduced FPG, increased glucose infusion rate and glucose utilization rate, decreased endogenous glucose production, and increased glucose uptake into liver in the insulin infusion stage of a hyperinsulinemic-euglycemic clamp versus those in vehicle-treated rats

FPG (day 15) Basal stage
Insulin infusion stage
Glucose uptake into peripheral tissues during insulin infusion stage
Plasma glucose (mg/dl) Plasma glucose (mg/dl) Urinary glucose loss rate (mg · kg−1 · min−1) Glucose utilization rate(mg · kg−1 · min−1) Plasma glucose (mg/dl) Urinary glucose loss rate (mg · kg−1 · min−1) Glucose infusion rate (mg · kg−1 · min−1) Glucose utilization rate (mg · kg−1 · min−1) Hepatic glucose production (mg ·kg−1 · min−1) Rg′ (liver) (ng · kg−1 · min−1) Rg′ (skeletal muscle) (ng · kg−1 · min−1) Rg′ (white adipose tissue) (ng · kg−1 · min−1)
Vehicle 295.2 ± 19.5 402 ± 30 0.35 ± 0.15 3.3 ± 0.3 122.8 ± 0.4 0.1 ± 0.05 2.6 ± 0.4 5.3 ± 0.15 3.0 ± 0.32 4.7 ± 0.46 4.2 ± 0.58 0.4 ± 0.06
Dapagliflozin 138.2 ± 7.4 307 ± 19 0.014 ± 0.01* 3.9 ± 0.27 121.7 ± 0.6 0.02 ± 0.01 6.0 ± 0.6 6.6 ± 0.32 0.7 ± 0.4 7.2 ± 0.32 4.3 ± 0.52 0.6 ± 0.1
  • *

    * P < 0.05,

  • P < 0.01,

  • P < 0.005, each vs. vehicle. Rg′, rate of glucose uptake into tissue.

This Article

  1. Diabetes vol. 57 no. 6 1723-1729